|Bid||3.5800 x 800|
|Ask||3.6900 x 1300|
|Day's Range||3.3710 - 3.9165|
|52 Week Range||2.0000 - 9.5600|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will chair the Company's scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of PAD. Dr. Kevil is considered a foremost expert in the development and analysis of various small molecules, biologics, disease indications, pharmaceutical, medical device, and drug delivery systems.
JanOne Inc. (NASDAQ:JAN) a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, announced the hiring of Tony Giordano, Ph.D. to serve as its Chief Scientific Officer.
JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, today announced a licensing agreement for TV1001SR, a treatment for Peripheral Artery Disease, commonly called PAD. The agreement with LSU Health Shreveport, UAB Research Foundation, and TheraVasc, Inc., gives JanOne a worldwide, exclusive license for TV1001SR along with a portfolio of 30 patents and other intellectual property relating to the sustained release of sodium nitrite.
LAS VEGAS, Sept. 12, 2019 /PRNewswire/ -- JanOne, Inc. (NASDAQ: JAN), a newly launched initiative with the focused intent of offering innovative, actionable solutions to end the opioid crisis, is proud to name host of America This Week and financial commentator Eric Bolling as its President and Chairman. As one personally affected by the opioid scourge, Bolling has dedicated himself to fighting the opioid epidemic by executing the mission of JanOne: To help to end the opioid crisis by, among other things, developing revolutionary pain medications to replace today's highly addictive and often fatal opioids. "I am elated to become part of JanOne and to help fulfill the mission of developing alternative, non-opioid pain drugs," Bolling said.
LAS VEGAS, Sept. 11, 2019 /PRNewswire/ -- Appliance Recycling Centers of America, Inc. (NASDAQ: JAN) today announced that, on September 10, 2019, the company has been renamed JanOne Inc. and, effective this morning, now trades under the ticker symbol JAN, with a new CUSIP number (47089W 104). The company's new name, JanOne, expresses the start of a new day in the fight against the opioid epidemic. January One is the first day of a New Year – a day of optimism, resolution, and hope. JanOne affirms the company's strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation's history.